Skip to main content

Physician Search

 


Displaying 1 - 1 of 1

TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers

Multiple Cancer Types

TTX-080-01 is a Phase 1, open label, dose escalation and dose expansion clinical study to determine the safety, tolerability, and recommended Phase 2 dose of TTX-080 monotherapy (HLA-G inhibitor) and in combination with either pembrolizumab (PD-1 inhibitor) or cetuximab (EGFR inhibitor) in patients with advanced refractory / resistant solid malignancies. The study is enrolling in the dose expansion cohorts.
Miscellaneous, Phase I
I
Keedy, Vicki
NCT04485013
VICCMD2172